Design of polymeric carriers for cancer-specific gene targeting: Utilization of abnormal protein kinase Cα activation in cancer cells

Journal of the American Chemical Society

Volumn 130, Issue 45, 2008, Pages 14906-14907

  Kang, Jeong Hun ^a,b   Asai, Daisuke ^c   Kim, Jong Hwan ^d   Mori, Takeshi ^a   Toita, Riki ^a   Tomiyama, Tetsuro ^a   Asami, Yoji ^a   Oishi, Jun ^a   Sato, Yuko T ^a,b   Niidome, Takuro ^a   Jun, Byungdug ^d   Nakashima, Hideki ^b,c   Katayama, Yoshiki ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (3 AMINOPROPYL) 3 INDOLYL] 4 (1 METHYL 3 INDOLYL) 1H PYRROLE 2,5 DIONE; GREEN FLUORESCENT PROTEIN; POLYMER; PROTEIN KINASE C ALPHA; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PHOSPHORYLATION; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNITS; DNA; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE TRANSFER TECHNIQUES; HUMANS; LUCIFERASES; MELANOMA, EXPERIMENTAL; MICE; PEPTIDES; PHOSPHORYLATION; PLASMIDS; SUBSTRATE SPECIFICITY; TRANSFECTION;

EID: 57349097756     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja805364s     Document Type: Article

References (14)

1. Pack, D. W.; Hoffman, A. S.; Pun, S.; Stayton, P. S. Nat. Rev. Drug Discov. 2005, 4, 581-593.
2. (a) Bonini, C.; Bondanza, A.; Perna, S. K.; Kaneko, S.; Traversari, C.; Ciceri, F.; Bordignon, C. Mol. Ther. 2007, 15, 1248-1252.
3. (b) Portsmouth, D.; Hlavaty, J.; Renner, M. Mol. Asp. Med. 2007, 28, 4-41.
4. (a) Zugates, G. T.; Anderson, D. G.; Little, S. R.; Lawhorn, I. E. B.; Langer, R. J. Am. Chem. Soc. 2006, 128, 12726-12734.
5. (b) Russ, V.; Wagner, E. Pharm. Res. 2007, 24, 1047-1057.
6. (c) Oishi, M.; Nagasaki, Y.; Itaka, K.; Nishiyama, N.; Kataoka, K. J. Am. Chem. Soc. 2005, 127, 1624-1625.
7. van Gaal, E. V. B.; Hennink, W. E.; Crommelin, D. J. A.; Mastrobattista, E. Pharm. Res. 2006, 23, 1053-1074.
8. (a) Oishi, J.; Kawamura, K.; Kang, J.-H.; Kodama, K.; Sonoda, T.; Murata, M.; Niidome, T.; Katayama, Y. J. Controlled Release 2006, 110, 431-436.
9. (b) Kawamura, K.; Oishi, J.; Kang, J.-H.; Kodama, K.; Sonoda, T.; Murata, M.; Niidome, T.; Katayama, Y. Biomacromolecules 2005, 6, 908-913.
10. (a) Hofmann, J. Curr. Cancer Drug Targets 2004, 4, 125-146.
11. (b) O'Brian, C. A.; Chu, F.; Bornmann, W. G.; Maxwell, D. S. Experts Rev. Anticancer Ther. 2006, 6, 175-186.
12. Kang, J.-H.; Asai, D.; Yamada, S.; Toita, R.; Oishi, J.; Mori, T.; Niidome, T.; Katayama, Y. Proteomics 2008, 8, 2006-2011.
13. Wilkinson, S. E.; Parker, P. J.; Nixon, J. S. Biochem. J. 1993, 294, 335-337.
14. Cook, P. F.; Neville, M. E., Jr.; Vrana, K. E.; Hartl, F. T.; Roskoski, R., Jr. Biochemistry 1982, 21, 5794-5799.